CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cell Immunotherapy For Adult B Cell Malignancies

CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cell Immunotherapy For Adult B Cell Malignancies

Cameron J. Turtle, MD, PhD, covers the background and rationale for CD19 CAR-T cell therapy, clinical responses and approaches to mitigate toxicity.


Created by

UW Medicine Provider Resource

Related Presenters

Cameron Turtle, MD, PhD

Cameron Turtle, MD, PhD

Biography Cameron Turtle, M.D., Ph.D., is a hematology oncologist at SCCA, a UW assistant professor of Oncology and Medicine and a research associate at Fred Hutchinson Cancer Research Center. Patients with hematologic malignancies are ...

View full profile